Each agent effectively disrupts separate modules of a common axis that results in downregulation of NF-κB; thus, we hypothesized that simultaneous disruption of this oncogenic axis at the 19 S proteasome (via VLX1570) and directly at the BCR/MY88L265P module (via ibrutinib) would result in enhanced tumor kill. Here, BCR is linked to neoplasm.